Fetisov Timur I, Menyailo Maxim E, Ikonnikov Alexander V, Khozyainova Anna A, Tararykova Anastasia A, Kopantseva Elena E, Korobeynikova Anastasia A, Senchenko Maria A, Bokova Ustinia A, Kirsanov Kirill I, Yakubovskaya Marianna G, Denisov Evgeny V
Research Institute of Molecular and Cellular Medicine, Peoples' Friendship University of Russia (RUDN University), 115093 Moscow, Russia.
N.N. Blokhin National Medical Research Center of Oncology, 115478 Moscow, Russia.
J Clin Med. 2024 Nov 26;13(23):7176. doi: 10.3390/jcm13237176.
Undifferentiated pleomorphic sarcoma (UPS) is a highly malignant mesenchymal tumor that ranks as one of the most common types of soft tissue sarcoma. Even though chemotherapy increases the 5-year survival rate in UPS, high tumor heterogeneity frequently leads to chemotherapy resistance and consequently to recurrences. In this study, we characterized the cell composition and the transcriptional profile of UPS with resistance to chemotherapy at the single cell resolution. A 58-year-old woman was diagnosed with a 13.6 × 9.3 × 6.0 cm multi-nodular tumor with heterogeneous cysto-solid structure at the level of the distal metadiaphysis of the left thigh during magnetic resonance tomography. Morphological and immunohistochemical analysis led to the diagnosis of high-grade (G3) UPS. Neoadjuvant chemotherapy, surgery (negative resection margins), and adjuvant chemotherapy were conducted, but tumor recurrence developed. The UPS sample was used to perform single-cell RNA sequencing by chromium-fixed RNA profiling. Four subpopulations of tumor cells and seven subpopulations of tumor microenvironment (TME) have been identified in UPS. The expression of chemoresistance genes has been detected, including (doxorubicin and ifosfamide), , , , and (doxorubicin), and (gemcitabine) in tumor cells and (gemcitabine) in TME. This study provides the first description of the single-cell transcriptome of UPS with resistance to two lines of chemotherapy, showcasing the gene expression in subpopulations of tumor cells and TME, which may be potential markers for personalized cancer therapy.
Int J Surg Case Rep. 2023-8
Surg Oncol Clin N Am. 2022-7
Br J Cancer. 2025-1
Oncogene. 2024-5
Cancer Commun (Lond). 2024-3
Cell Biosci. 2023-11-29
Int J Mol Sci. 2023-7-31